FINWIRES · TerminalLIVE
FINWIRES

Micron's Long-Term Customer Contracts Strengthen Earnings Durability, RBC Says

By

Micron Technology (MU) newly signed long-term customer agreements are emerging as a key source of margin support and downside protection as the memory upcycle extends into 2027, RBC Capital Market said Wednesday in a report.

The 16 strategic contracts, covering roughly a quarter of Micron's revenue, include pricing floors that help protect profitability even if demand softens, the report said.

The agreements span portions of Micron's output in DRAM, the working memory inside computers and servers, and NAND, the storage memory used in solid-state drives and phones, the report said. The take-or-pay structure and minimum-revenue commitments reduce downside risk, RBC said.

Rising production of HBM, the high-bandwidth memory used in AI accelerators, is driving strong momentum for Micron, with HBM revenue already above $1 billion and market share topping 20%, the report said.

The firm expects DRAM pricing to keep climbing through 2027 as AI demand remains robust, RBC said. NAND pricing is also benefiting from firm conditions, though some moderation may emerge as the high base and contract structures settle in, the report said.

RBC raised its price target on Micron stock to $1,500 from $1,200 and maintained its outperform rating.

On Thursday, Micron reported fiscal Q3 results and Q4 guidance that exceeded consensus forecasts.

Price: $1182.44, Change: $+134.52, Percent Change: +12.84%

Related Articles

Wire

Arovella Therapeutics Secures Ethics Approval for First-in-Human Study of Blood Cancer Drug Candidate

Arovella Therapeutics (ASX:ALA) received ethics approval from The Alfred and Bellberry Human Research Ethics Committees to begin its phase 1 first-in-human clinical trial of ALA-101 drug candidate, a chimeric antigen receptor invariant natural killer T (CAR-iNKT) cell therapy for patients with relapsed or refractory lymphomas and leukemias, according to a Thursday Australian bourse filing.The trial is expected to involve up to seven clinical sites across Australia and New Zealand, the filing said. It will evaluate the safety, tolerability, and preliminary anti-tumor activity of ALA-101.The company remains on track to begin first patient dosing in the September quarter.Arovella Therapeutics' shares fell past 1% in recent trading on Thursday and earlier hit their lowest since September 2023.

ASX:ALA
Wire

Update: Tourism Holdings Receives Additional Non-Binding Takeover Offer From Unnamed 'Credible Strategic' Buyer; Shares Over Two-Year High

(Updates to add stock movement in the headline and the last paragraph)Tourism Holdings (ASX:THL, NZE:THL) received an additional non-binding indicative offer from an unnamed "credible strategic" buyer to acquire 100% of the company at a proposed price of NZ$3.30 to NZ$3.40 per share, according to a Thursday filing with the New Zealand and Australian bourses.The proposal is subject to customary conditions, including due diligence, board approval, regulatory and third-party consents, and unanimous board recommendation, subject to standard fiduciary carve-outs, per the filing.The company has allowed the bidder to conduct due diligence under a confidentiality agreement while emphasizing that no decision has been made and there is no assurance that a transaction will proceed, the filing said.The company is also engaged in discussions with the BGH consortium on a similar confidentiality agreement to support due diligence, the filing added.The company's shares on the New Zealand bourse rose 12% in Thursday trading and earlier reached their highest level since April 2024, while Australian shares gained 11%.

ASX:THLNZE:THL
Wire

Lockheed Martin Wins Up to $35 Billion Contract to Expand US Missile Defense Production

Lockheed Martin (LMT) won a seven-year US government contract worth up to $35 billion to quadruple production of its Terminal High Altitude Area Defense interceptors.The award is one of the first major multiyear procurement contracts under the Pentagon's new acquisition strategy, Lockheed Martin said Wednesday in a statement.The contract implements a THAAD framework agreement signed in January and is intended to support long-term production scaling and strengthen the missile-defense industrial base for the US and its allies, the company said.Lockheed Martin shares rose 0.9% in after-hours trading.

$LMT